Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has bee...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	adenocarcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy epidermal growth factor receptor wild-type Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8dc7d6ca561e488d862a1aaf5bfc93c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8dc7d6ca561e488d862a1aaf5bfc93c8
record_format	dspace
spelling	oai:doaj.org-article:8dc7d6ca561e488d862a1aaf5bfc93c82021-12-02T06:32:59ZTrajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study1179-2728https://doaj.org/article/8dc7d6ca561e488d862a1aaf5bfc93c82017-02-01T00:00:00Zhttps://www.dovepress.com/trajectory-of-chemotherapy-for-patients-with-egfr-wild-type-advanced-p-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proportions of patients treated with first- to third-line chemotherapy and to find influential factors for the introduction of chemotherapy and survival benefit from chemotherapy.Materials and methods: Data were collected retrospectively on patients who met the following criteria: adenocarcinoma, diagnosed between June 2007 and March 2015 at our hospital, stage IIIB or IV, and EGFR wild type. A nonchemotherapy group of patients who did not receive chemotherapy was compared with a chemotherapy group of patients who received it. The patients who had received first- to third-line chemotherapy between June 2007 and November 2015 at our hospital were also analyzed.Results: During the study period, 46 patients did not receive chemotherapy, while 148, 89, and 48 received first-, second- and third-line chemotherapy, respectively. As predictive factors for unlikely chemotherapy, multivariate logistic analysis detected Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, hemoglobin <13.2 g/dL, creatinine clearance (Ccr) <50.4 mL/min, and CRP ≥0.53 mg/dL. As factors predicting shorter survival after chemotherapy, multivariate Cox proportional-hazard analyses detected age ≥75 years, ECOG PS ≥2, lower lymphocyte counts, and higher CRP for the first line; female, higher neutrophil counts, lower lymphocyte counts, reduced Ccr, hyponatremia, and shorter interval between first- and second-line chemotherapy for the second line; and age ≥75 years, body mass index <18.5 kg/m2, higher neutrophil counts, lower lymphocyte counts, hyponatremia, higher lactate dehydrogenase, and higher CRP for the third line.Conclusion: Approximately 76% of patients were treated with first-line chemotherapy. Of those patients, 61% and 34% proceeded to second- and third-line chemotherapy, respectively. For patients with poor PS, anemia, reduced Ccr, and higher CRP, it is difficult to introduce chemotherapy. Keywords: adenocarcinoma, non-small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, EGFR wild typeMinami SOgata YIhara SYamamoto SKomuta KDove Medical Pressarticleadenocarcinomanon-small cell lung cancerfirst-line chemotherapysecond-line chemotherapythird-line chemotherapyepidermal growth factor receptor wild-typeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 21-30 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	adenocarcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy epidermal growth factor receptor wild-type Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	adenocarcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy epidermal growth factor receptor wild-type Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Minami S Ogata Y Ihara S Yamamoto S Komuta K Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
description	Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proportions of patients treated with first- to third-line chemotherapy and to find influential factors for the introduction of chemotherapy and survival benefit from chemotherapy.Materials and methods: Data were collected retrospectively on patients who met the following criteria: adenocarcinoma, diagnosed between June 2007 and March 2015 at our hospital, stage IIIB or IV, and EGFR wild type. A nonchemotherapy group of patients who did not receive chemotherapy was compared with a chemotherapy group of patients who received it. The patients who had received first- to third-line chemotherapy between June 2007 and November 2015 at our hospital were also analyzed.Results: During the study period, 46 patients did not receive chemotherapy, while 148, 89, and 48 received first-, second- and third-line chemotherapy, respectively. As predictive factors for unlikely chemotherapy, multivariate logistic analysis detected Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, hemoglobin <13.2 g/dL, creatinine clearance (Ccr) <50.4 mL/min, and CRP ≥0.53 mg/dL. As factors predicting shorter survival after chemotherapy, multivariate Cox proportional-hazard analyses detected age ≥75 years, ECOG PS ≥2, lower lymphocyte counts, and higher CRP for the first line; female, higher neutrophil counts, lower lymphocyte counts, reduced Ccr, hyponatremia, and shorter interval between first- and second-line chemotherapy for the second line; and age ≥75 years, body mass index <18.5 kg/m2, higher neutrophil counts, lower lymphocyte counts, hyponatremia, higher lactate dehydrogenase, and higher CRP for the third line.Conclusion: Approximately 76% of patients were treated with first-line chemotherapy. Of those patients, 61% and 34% proceeded to second- and third-line chemotherapy, respectively. For patients with poor PS, anemia, reduced Ccr, and higher CRP, it is difficult to introduce chemotherapy. Keywords: adenocarcinoma, non-small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, EGFR wild type
format	article
author	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_facet	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_sort	Minami S
title	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
title_short	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
title_full	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
title_fullStr	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
title_full_unstemmed	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
title_sort	trajectory of chemotherapy for patients with egfr wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/8dc7d6ca561e488d862a1aaf5bfc93c8
work_keys_str_mv	AT minamis trajectoryofchemotherapyforpatientswithegfrwildtypeadvancedpulmonaryadenocarcinomaasingleinstitutionretrospectivestudy AT ogatay trajectoryofchemotherapyforpatientswithegfrwildtypeadvancedpulmonaryadenocarcinomaasingleinstitutionretrospectivestudy AT iharas trajectoryofchemotherapyforpatientswithegfrwildtypeadvancedpulmonaryadenocarcinomaasingleinstitutionretrospectivestudy AT yamamotos trajectoryofchemotherapyforpatientswithegfrwildtypeadvancedpulmonaryadenocarcinomaasingleinstitutionretrospectivestudy AT komutak trajectoryofchemotherapyforpatientswithegfrwildtypeadvancedpulmonaryadenocarcinomaasingleinstitutionretrospectivestudy
_version_	1718399885804306432

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study

Ejemplares similares